药物化学期刊JMC Annotation专栏重磅药物分析.docx

A—?”JN?A?itotaticnMf?°??fi?? 04

STX-721:EGFR/HER2Exon20ins @‘J)fü$?*?

KT-413:IRAK4ê*g???

30

3

1.2.4GLPG-3667@Ill n@$8@§k {g

GLPG-3667C@€J3?@@@@§§CC, _1@iS@ @@]8)6CE,)g “GLPG-3667 1a?§8IrC i? 2,/f]T

z”^TzIfifl/t

z”^TzIfifl/tw(NCIO 2*J5ZfI2(SLE,NC

(12)o

@A:https://S/clinical-progress-detail/23940a80a9232a92ea5d88ad0a5a3052

6L

6Ls3667Aft/Bt/t9ttRaT1E4x/￥Vn. VmEtéfE.aP, .Vn.XMaExl1:zEmVn?x/4a6 IzJei%

fg?,Q?GLPs3667 fetafija.la=.s /ti?aoaze?iaaoayixr+strse?zo

=acLc-3667A6rNlNs W,remind— aMR#\@,frt6ii6NRAx?T. wxzTs8J5Jsx

:0,Tat6G3R RD6TRfiE,DB:@1NeAE@tBaas fi@.ANRt8:IT:R—1NstcAAa,

13GLPG-366T@ €[n

@A%:/drug/0e60f7f401ddb3ac2fc2f2

13

STX-721:EGFR/HER2Exon20insifi?g?llOg?g?

1.3.1EGFR/HER2Exon20ins)gg?ffRffI2a@W (fi)E @

1.3.1EGFR/HER2Exon20ins)gg?ffRffI2a

@W (fi)E @(EGFR)$0 UEI?1-I2@T 182(HER2)@3gJ@@@%(NSCLC)T0 T€(6@@1f1$B

?,.f€?2@EGFR@@§g)IfU?N?(TKI)§0Osimertinib(BMPu)11tt EGFR??t%(L858R,Exon19deletion) T?!7?EGFR/HER2Exon20TSA %(Exon20ins)gtt$xX,fZiltLExon20ins % @@f1 li?il

EGFRexon20x

HER2exon20

EGFR20@s?tt ?j?e?izi?

a*a(.za?ei?ia?sa tttis+a

@82§$%|EGFR

EGFRexon20x

HER2exon20

°.fRM1F@1?J?UTTL1

?r.v.R6sttf4B ?6ah6L-a3M

Sevabertinib

EGFRxEGFR

exon20xHER2xHER2exon20xHER4

HanmiPharmaceutical

Co.,Ltd.

FWD-1509

EGFRexon20x

HER2

ORIC-114

STX-721

EGFRexon20x

HER2

ScorpionTherapeutics,

lnc.

xm se.°,(soa? xc*e ?ssms üassas*?a

NIP-142 EGFRexon20xEGFR @?2.J..j.st?J?? aaszasxxR6ù?6!IaiCa1?g

DS-2087b EGFRexon20x§$dg

HER2exon20

.??t3=J?m DaiichiSankyoCo.,Ltd. ?elmnr

LDC0496LDC8201

EGFRexon20x3EJ@s?% .j??s=??? PearlRiverBioGmbH !lanr

HER2exon20

14STX-721exon20xRiverB”bH69 @A?g: @://synapse.zhihuiya.Erfl7I*JgR2qE y

14

STX-721

exon20x

RiverB”

bH

1.3.2?%

STX-721.STX-721I

STX-721.

C413:PR0TACIRAK4@O§?

1.4.1IRAK4]glgj/[j§)f@fl?u

1.4.1IRAK4]glgj/[j§)f@